A
Anthos Therapeutics
Clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic options for the treatment of cardiovascular metabolic diseases
About Anthos Therapeutics
Anthos Therapeutics is a clinical-stage biopharmaceutical company that operates in the healthcare sector, specifically in the development and commercialization of innovative therapies for cardiovascular and metabolic diseases. Their primary focus is on a novel drug, Abelacimab, which is designed to suppress Factor XI, a new antithrombotic target, and its activated form, Factor XIa. This drug is being developed to provide protection from arterial and venous thromboembolic events, which are blood clots that can cause strokes or heart attacks, while reducing the risk of significant bleeding, a common side effect of current anticoagulants.
Read full description
The company's business model revolves around the research, development, and eventual commercialization of their drug therapies. They generate revenue through the successful development and subsequent sale of these therapies to healthcare providers and patients. Their primary market is individuals suffering from cardiovascular and metabolic diseases, a demographic that represents a significant portion of the global population.
Anthos Therapeutics' latest results show that Abelacimab has demonstrated a significant reduction in bleeding compared to Rivaroxaban, a commonly used anticoagulant. This suggests that Abelacimab could potentially meet a major unmet need in the market for safer and more effective anticoagulation therapies.
At a glance
- Status
- Acquired
- Founded
- 2018
- Headquarters
- Cambridge, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 59.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Risk Management, Biotechnology, Cardiology and cardiovascular, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Feb 2025 | $925M | $925M | Novartis | ↗ |
| EARLY VCOther financing | Feb 2019 | $250M | $1B | Novartis · Blackstone | — |
Growth signals
Latest recorded traffic for Anthos Therapeutics is 1.6K monthly website visits, down 20% over the last three months. Anthos Therapeutics's team declined 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Novartis
Blackstone
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Anthos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anthos Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.